Dr. James Robinson, a health economist at University of California at Berkley, criticized hospitals’ “buy and bill” drug acquisition process.
U.C. Berkeley Researcher Proposes 340B Be Limited to the Indigent or that Providers Pass on their Discounts to Insurance Industry
Rich Daly Editor in Chief
Views
A University of California at Berkeley academic is proposing a series of major reforms to the 340B discount drug program [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
